tbuckley/cabot-search huggingface dataset:
Colorectal cancer statistics, 2017
Authors: Rebecca L. Siegel, Kimberly D. Miller, Stacey A. Fedewa, Dennis J. Ahnen, Reinier G. S. Meester, Afsaneh Barzi, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2017)

Colorectal cancer (CRC) is one of the most common malignancies in the United States. Every 3 years, the American Cancer Society provides an update of CRC incidence, survival, and mortality rates and trends. Incidence data through 2013 were provided by the Surveillance, Epidemiology, and End Results program, the National Program of Cancer Registries, and the North American Association of Central Cancer Registries. Mortality data through 2014 were provided by the National Center for Health Statistics. CRC incidence rates are highest in Alaska Natives and blacks and lowest in Asian/Pacific Islanders, and they are 30% to 40% higher in men than in women. Recent temporal patterns are generally similar by race and sex, but differ by age. Between 2000 and 2013, incidence rates in adults aged ≥50 years declined by 32%, with the drop largest for distal tumors in people aged ≥65 years (incidence rate ratio [IRR], 0.50; 95% confidence interval [95% CI], 0.48-0.52) and smallest for rectal tumors in ages 50 to 64 years (male IRR, 0.91; 95% CI, 0.85-0.96; female IRR, 1.00; 95% CI, 0.93-1.08). Overall CRC incidence in individuals ages ≥50 years declined from 2009 to 2013 in every state except Arkansas, with the decrease exceeding 5% annually in 7 states; however, rectal tumor incidence in those ages 50 to 64 years was stable in most states. Among adults aged <50 years, CRC incidence rates increased by 22% from 2000 to 2013, driven solely by tumors in the distal colon (IRR, 1.24; 95% CI, 1.13-1.35) and rectum (IRR, 1.22; 95% CI, 1.13-1.31). Similar to incidence patterns, CRC death rates decreased by 34% among individuals aged ≥50 years during 2000 through 2014, but increased by 13% in those aged <50 years. Progress against CRC can be accelerated by increasing initiation of screening at age 50 years (average risk) or earlier (eg, family history of CRC/advanced adenomas) and eliminating disparities in high-quality treatment. In addition, research is needed to elucidate causes for increasing CRC in young adults. CA Cancer J Clin 2017. © 2017 American Cancer Society. CA Cancer J Clin 2017;67:177-193. © 2017 American Cancer Society.
Characterization of Regulatory T Cell Reconstitution after Allogeneic Hematopoietic Cell Transplantation: Expansion Potential at 100 Days Predicts De Novo Graft-Versus-Host Disease By Six Months Post-Transplantation
Authors: Julie R. Boiko, Annie Im, Xiaohua Chen, Memphis J Hill, Paul Szabolcs
Journal: Blood (2015)
Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis
Authors: Gonzalo Sapisochin, Aisling Barry, Mark Doherty, Sandra Fischer, Nicolas Goldaracena, Roizar Rosales, Moises Russo, Rob Beecroft, Anand Ghanekar, Mamatha Bhat, James Brierley, Paul D. Greig, Jennifer J. Knox, Laura A. Dawson, David R. Grant
Journal: Journal of Hepatology (2017)
Clinical Outcome of a Second Autologous Hematopoietic Stem Cell Transplant (HCT) for Non-Hodgkin (NHL) and Hodgkin Lymphoma (HL) Relapsing after a First Autotransplant.
Authors: Sonali M. Smith, Koen van Besien, Jeanette Carreras, Julie M. Vose, Hillard M. Lazarus, Parameswaran Hari
Journal: Blood (2006)
Quality Improvement in Cardiac Services in India
Authors: Amitava Banerjee
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived
Authors: Sara Farshchi Zarabi, Steven M. Chan, Vikas Gupta, Dina Khalaf, Andrzej Lutynski, Mark D. Minden, Amr Rostom, Anna Rydlewski, Andre C. Schuh, Hassan Sibai, Karen W.L. Yee, Aaron D. Schimmer
Journal: Blood (2016)
Detection of Molecular Relapse of AML by Very Frequent Quantitative Monitoring of Different Molecular Markers (Fusion Transcripts and WT1) in Different Compartments (Peripheral Blood-PB, Bone Marrow-BM, and Selected CD34+ Bone Marrow Cells) and Its Treatment with Chemotherapy or Gemtuzumab Ozogamicin.
Authors: Jiri Mayer, Ivo Palasek, Zdenek Pospisil, Sona Struncova, Dana Dvorakova, Marek Borsky, Martin Klabusay, Michael Doubek, Yvona Brychtova, Zdenek Racil
Journal: Blood (2006)
An Exercise Training Programme Produces Significant Improvements in Quality of Life (QoL), Muscle Strength and Cardiorespiratory Function in Patients with Myeloma.
Authors: Lara J. Groeneveldt, Rachel Garrod, Kwee L. Yong, Flora Dangwa, Andrew P. Jewell, Ken van Someren, Neil Rabin, Lisa Nicholls, Shirley P. D’Sa
Journal: Blood (2007)
Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women
Authors: Marjanka K. Schmidt, Alexandra J. van den Broek, Rob A. E. M. Tollenaar, Vincent T. H. B. M. Smit, Pieter J. Westenend, Mariël Brinkhuis, Wolter J. W. Oosterhuis, Jelle Wesseling, Maryska L. Janssen-Heijnen, Jan J. Jobsen, Agnes Jager, Adri C. Voogd, Flora E. van Leeuwen, Laura J. van ’t Veer
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: The primary aim of the study was to investigate prognosis and long-term survival in young breast cancer patients with a BRCA1 or BRCA2 germline mutation compared with noncarriers. The secondary aim was to investigate whether differences in survival originate from associations with tumor characteristics, second cancers, and/or treatment response. Methods: We established a cohort of invasive breast cancer patients diagnosed younger than age 50 years in 10 Dutch hospitals between 1970 and 2003. BRCA1/2 testing of most prevalent mutations was mainly done using DNA isolate from formalin-fixed paraffin-embedded nontumor tissue. Survival estimates were derived using Cox regression and competing risk models. Results: In 6478 breast cancer patients, we identified 3.2% BRCA1 and 1.2% BRCA2 mutation carriers. BRCA1 mutation carriers had a worse overall survival independent of clinico-pathological/treatment characteristics, compared with noncarriers (adjusted hazard ratio [HR] = 1.20, 95% confidence interval [CI] = 0.97 to 1.47), though only statistically significant in the first five years of follow-up (adjusted HR = 1.40, 95% CI = 1.07 to 1.84). A large part of the worse survival was explained by incidence of ovarian cancers. Breast cancer–specific, disease-free, and metastasis-free survival results were less pronounced and mostly statistically nonsignificant but in the same direction with those of overall survival. Overall survival was worse, although not statistically significantly, within the ER-negative or ER-positive, grade 3, and small tumor subgroups. The worse survival was most pronounced in non-chemotherapy-treated patients (adjusted HR = 1.54, 95% CI = 1.08 to 2.19). Power for BRCA2 mutation carriers was limited; only after five years' follow-up overall survival was worse (adjusted HR = 1.47, 95% CI = 1.00 to 2.17). Conclusions:BRCA1/2 mutation carriers diagnosed with breast cancer before age 50 years are prone to a worse survival, which is partly explained by differences in tumor characteristics, treatment response, and second ovarian cancers.
Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies
Authors: Ian H Gabriel, Juliet Sharon, Eduardo Olavarria, Amin Rahemtulla, Edward Kanfer, David Marin, Dragana Milojkovic, Katayoun Rezvani, Donald MacDonald, Richard M. Szydlo
Journal: Blood (2008)
Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept
Authors: Marina Ramirez‐Alvarado, David R. Barnidge, David L. Murray, Angela Dispenzieri, Marta Marin‐Argany, Christopher J. Dick, Shawna A. Cooper, Samih H Nasr, Christopher J. Ward, Surendra Dasari, Víctor H. Jiménez‐Zepeda, Nelson Leung
Journal: American Journal of Hematology (2017)

Abstract Immunoglobulin light chain (AL) amyloidosis is a fatal complication of B‐cell proliferation secondary to deposition of amyloid fibrils in various organs. Urinary exosomes (UEX) are the smallest of the microvesicles excreted in the urine. Previously, we found UEX of patients with AL amyloidosis contained immunoglobulin light chain (LC) oligomers that patients with multiple myeloma did not have. To further explore the role of the LC oligomers, UEX was isolated from an AL amyloidosis patient with progressive renal disease despite achieving a complete response. LC oligomers were identified. Mass spectrometry (MS) of the UEX and serum identified two monoclonal lambda LCs. Proteomics of the trypsin digested amyloid fragments in the kidney by laser microdissection and MS analysis identified a λ6 LC. The cDNA from plasma cell clone was from the IGLV‐ 6‐57 family and it matched the amino acid sequences of the amyloid peptides. The predicted mass of the peptide product of the cDNA matched the mass of one of the two LCs identified in the UEX and serum. UEX combined with MS were able to identify 2 monoclonal lambda LCs that current clinical methods could not. It also identified the amyloidogenic LC which holds potential for response assessment in the future.
Human Blood Dendritic Cells Induce Tregs Through the PGE2-Independent Expression of an Active Form of IDO2 Enzyme
Authors: Sara Trabanelli, Darina Ocadlikova, Marilena Ciciarello, Valentina Salvestrini, Cecilia Evangelisti, Richard Metz, Lisa Laury-Kleintop, George Prendergast, Antonio Curti, Roberto M. Lemoli
Journal: Blood (2012)
Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network
Authors: Karin Hohloch, P.L. Zinzani, Werner Linkesch, Andrzej Deptala, Jurczak Wojciech, Cheolwon Suh, Michael Lorsbach, Christiane Windemuth-Kiesselbach, Lorenz H. Truemper
Journal: Blood (2008)
Mitochondrial DNA sequencing demonstrates clonality of peritoneal implants of borderline ovarian tumors
Authors: Giulia Girolimetti, Pierandrea De Iaco, Martina Procaccini, Riccardo Panzacchi, Ivana Kurelac, Laura Benedetta Amato, Giulia Dondi, Giacomo Caprara, Claudio Ceccarelli, Donatella Santini, Anna Maria Porcelli, Anna Myriam Perrone, Giuseppe Gasparre
Journal: Molecular Cancer (2017)

Borderline ovarian tumors are rare low malignant potential neoplasms characterized by the absence of stromal invasion, whose main prognostic factors are stage and type of peritoneal implants. The latter are defined as invasive when cell proliferation invades the underlying tissue (peritoneal surface, omentum and intestinal wall), or noninvasive. It is still unknown if these implants are metastatic spread from the primary ovarian mass or a neoplastic transformation de novo of the peritoneal surface. Mitochondrial DNA sequencing was performed to assess clonality in eight patients presenting both borderline ovarian tumors and implants. In 37.5% of the cases, the same mitochondrial DNA mutation was present in both borderline ovarian tumors and the peritoneal implant, being this evidence that implants may arise as a consequence of a spread from a single ovarian site.
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Authors: Anja Seckinger, Jose Antonio Delgado, Samuel Moser, Laura Moreno, Brigitte Neuber, Anna Grab, Susanne Lipp, Juana Merino, Felipe Prosper, Martina Emde, Camille Delon, Melanie Latzko, Reto Gianotti, Remo Lüoend, Ramona Murr, Ralf J. Hosse, Lydia Jasmin Harnisch, Marina Bacac, Tanja Fauti, Christian Klein, Aintzane Zabaleta, Jens Hillengass, Elisabetta Ada Cavalcanti-Adam, Anthony D. Ho, Michael Hundemer, Jesus F. San Miguel, Klaus Strein, Pablo Umaña, Dirk Hose, Bruno Paiva, Minh Diem Vu
Journal: Cancer Cell (2017)
Abstract P6-09-04: Nuclear grade has a limited role in predicting recurrence in DCIS following breast conserving surgery: A population-based study
Authors: S Nofech-Mozes, W Hanna, FL Baehner, R Saskin, A Tuck, S Sengupta, L Elavathil, PA Jani, M Bonin, MC Chang, E Slodkowska, L Paszat, E Rakovitch
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium.
Cloning of AML1-LAF4 Fusion Gene in Childhood T-Cell Acute Lymphoblastic Leukemia with t(2;21)(q11;q22) by Bubble PCR Method for cDNA.
Authors: Yoshiaki Chinen, Tomohiko Taki, Kazuhiro Nishida, Daisuke Shimizu, Takashi Okuda, Naohisa Yoshida, Chie Kobayashi, Kazutoshi Koike, Masahiro Tsuchida, Yasuhide Hayashi, Masafumi Taniwaki
Journal: Blood (2007)
Inhibition of protein kinases by anticancer DNA intercalator, 4-butylaminopyrimido[4′,5′:4,5]thieno(2,3- b )quinoline
Authors: HeggoduG. Rohit Kumar, Chethan S. Kumar, Hulihalli N. Kiran Kumar, Gopal M. Advi Rao
Journal: Acta Pharmaceutica Sinica B (2017)

Targeting protein kinases (PKs) has been a promising strategy in treating cancer, as PKs are key regulators of cell survival and proliferation. Here in this study, we studied the ability of pyrimido[4',5':4,5]thieno(2,3-b)quinolines (PTQ) to inhibit different PKs by performing computational docking and in vitro screening. Docking studies revealed that 4-butylaminopyrimido[4',5':4,5]thieno(2,3-b)quinoline (BPTQ) has a higher order of interaction with the kinase receptors than other PTQ derivatives. In vitro screening confirms that BPTQ inhibits VEGFR1 and CHK2, with the IC50 values of 0.54 and 1.70 µmol/L, respectively. Further, cytotoxicity of BPTQ was measured by trypan blue assay. Treatment with BPTQ decreased the proliferation of HL-60 cells with an IC50 value of 12 µmol/L and induces apoptosis, as explicated by the fall in the mitochondrial membrane potential, annexin V labeling and increased expression of caspase-3. Taken together, these data suggest that BPTQ possess ability to inhibit PKs and to induce cell death in human promyelocytic leukemia cells.
Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR
Authors: Madan Jagasia, Mukta Arora, Mary Flowers, Nelson J. Chao, Philip L. McCarthy, Joseph H. Antin, Brian J. Bolwell, Christopher Bredeson, Jean-Yves Cahn, Mitchell S. Cairo, Corey Cutler, Robert Peter Gale, Vikas Gupta, Michael D Haagenson, Mary M. Horowitz, Stephanie J. Lee, Mark R. Litzow, Steven Z. Pavletic, Alvaro Urbano, Daniel J. Weisdorf, Mei-Jie Zhang, Theresa Hahn
Journal: Blood (2010)
Abstract P3-06-05: Receptor-mediated binding of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 increases liposome binding, nuclear doxorubicin, DNA damage and efficacy relative to untargeted PEGylated liposomal doxorubicin (PLD/Doxil)
Authors: C Espelin, E Geretti, S Coma, Z Koncki, S Leonard, N Dumont, J Reynolds, I Molnar, T Wickham
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial
Authors: Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix J. F. Herth, Chau Thach, Robert Fogel, Petter Olsson, Francesco Patalano, Donald Banerji, Jadwiga A. Wedzicha
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).Objectives: We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an inhaled corticosteroid/long-acting β2-agonist combination versus a long-acting β2-agonist/long-acting muscarinic antagonist combination for exacerbation prevention.Methods: We conducted prespecified analyses of data from the FLAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily long-acting β2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50 μg with twice-daily long-acting β2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 μg in patients with one or more exacerbations in the preceding year. Subsequent post hoc analyses were conducted to address further cutoffs and endpoints.Measurements and Main Results: We compared treatment efficacy according to blood eosinophil percentage (<2% and ≥2%, <3% and ≥3%, and <5% and ≥5%) and absolute blood eosinophil count (<150 cells/μl, 150 to <300 cells/μl, and ≥300 cells/μl). Indacaterol/glycopyrronium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all severities, or moderate or severe) in the <2%, ≥2%, <3%, <5%, and <150 cells/μl subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium. Furthermore, the rate of moderate or severe exacerbations did not increase with increasing blood eosinophils. The incidence of pneumonia was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the <2% and ≥2% subgroups.Conclusions: Our prospective analyses indicate that indacaterol/glycopyrronium provides superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD.Clinical trial registered with www.clinicaltrials.gov (NCT01782326).
Government unveils plan to speed up payments for birth injuries
Authors: Clare Dyer
Journal: BMJ (2017)

Children who experience severe avoidable injuries at birth could be compensated more quickly under a new out-of-court redress scheme proposed by the Department of Health for England.1

The rapid resolution and redress (RRR) scheme also aims to reduce the number of such injuries by adoption of a learning culture, improve the experience for clinicians and families, and make more effective use of NHS resources.

The proposals, which are out for consultation until 26 May, come as the NHS litigation bill for maternity claims reaches nearly £500m (€580m; $610m) a year. The average payout in cases of severe birth injury, around 100 of which are settled each year, is £6.25m, and the average case takes …
Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease
Authors: Thomas Doetschman, Teodora Georgieva
Journal: Circulation Research (2017)

Genetic engineering of model organisms and cultured cells has for decades provided important insights into the mechanisms underlying cardiovascular development and disease. In the past few years the development of several nuclease systems has broadened the range of model/cell systems that can be engineered. Of these, the CRISPR (clustered regularly interspersed short palindromic repeats)/Cas9 (CRISPR-associated protein 9) system has become the favorite for its ease of application. Here we will review this RNA-guided nuclease system for gene editing with respect to its usefulness for cardiovascular studies and with an eye toward potential therapy. Studies on its off-target activity, along with approaches to minimize this activity will be given. The advantages of gene editing versus gene targeting in embryonic stem cells, including the breadth of species and cell types to which it is applicable, will be discussed. We will also cover its use in iPSC for research and possible therapeutic purposes; and we will review its use in muscular dystrophy studies where considerable progress has been made toward dystrophin correction in mice. The CRISPR/Ca9s system is also being used for high-throughput screening of genes, gene regulatory regions, and long noncoding RNAs. In addition, the CRISPR system is being used for nongene-editing purposes such as activation and inhibition of gene expression, as well as for fluorescence tagging of chromosomal regions and individual mRNAs to track their cellular location. Finally, an approach to circumvent the inability of post-mitotic cells to support homologous recombination-based gene editing will be presented. In conclusion, applications of the CRISPR/Cas system are expanding at a breath-taking pace and are revolutionizing approaches to gain a better understanding of human diseases.
Asynchronous control of unmanned aerial vehicles using a steady-state visual evoked potential-based brain computer interface
Authors: Lenis Meriño, Tapsya Nayak, Prasanna Kolar, Garrett Hall, Zijing Mao, Daniel J. Pack, Yufei Huang
Journal: Brain-Computer Interfaces (2017)

The goal of this study is to design an asynchronous steady-state visual evoked potential (SSVEP) BCI system to enable control of an unmanned aerial vehicle (UAV) with multiple commands. An SSVEP-based BCI system with six different flickering frequencies was constructed to realize six actuation commands for UAV control. In addition, asynchronous control was achieved by including a detection of the 'idle' brain state using a novel likelihood ratio test and the hover command was implemented for the idle state. Offline recording was conducted to evaluate the detection accuracies and a game-like online experiment was also conducted to assess the online performance of the proposed system. Forty-two subjects participated in offline recordings to evaluate the detection accuracy of commands as well as detection of the 'idle' state. An average error rate of 15% was obtained for detecting the six commands, whereas an average error rate of 23.06% was obtained for differentiating commands from idle brain states. For the online test, 11 subjects were recruited and all except two subjects successfully demonstrated control of the UAV by maneuvering the drone using all six commands and hover to acquire targets. Given our system design with a higher number of commands and online task difficulty, an average ITR of 0.98 bits/min was obtained. The developed SSVEP-based drone control system can execute a lot more commands than an imaginary motion-based drone control system and the asynchronous design significantly improves navigation. In addition, the proposed system can achieve good detection performance and ITR without any training.
TGFβ1 Induces MLL-Rearranged Acute Lymphoblastic Leukemia into Chemoresistant Quiescence in a Coordinated Manner with FLT3 Ligand
Authors: Minori Tamai, Yoshiyuki Furuichi, Shin Kasai, Norie Ando, Kumiko Goi, Takeshi Inukai, Masako Abe, Keiko Kagami, Kanji Sugita
Journal: Blood (2016)